摘要
目的观察原发性高血压病人凝血和纤溶活性的改变，探讨氯沙坦降压治疗后，对原发性高血压患者凝血和纤溶系统的影响。方法将30例1～3级原发性高血压病人和30例正常对照组进行比较。所有入选对象1个月内未服血管紧张素转换酶抑制剂及受体阻制剂，检测纤溶酶原激活物抑制剂-1（PAI-1）和D-二聚体（D-D）、血管性血友病因子（vWF）。高血压组予氯沙坦50～100mg/d治疗，疗程4周后再次检测PAI-1活性及D-D、vWF水平。结果高血压组PAI-1活性、D-D、vWF水平较正常对照组升高（P〈0．01）。高血压病人经氯沙坦4周治疗后，PAI-1活性及D-D、vWF水平较前明显下降（P〈0.01）。结论原发性高血压病人PAI-1、D-D、vWF明显升高，存在凝血、纤溶功能改变。氯沙坦除降压效果良好外，还能降低PAI-1、D-D、vWF水平。改善高血压患者的凝血、纤溶状况。
Objective To compare the coaglation and fibrinolysis condition in patients with essential hypertension （ EH） and in normal adult, to study influence of Losartan treatment on coagulation and fibrinolysis in patients with essential hypertension. Methods Plasminogen activator inhibitor-1 （ PAl-1 ） ,yon willebrand factor （ vWF） and D-dimcr （ D-D） were assessed in 30 EH cases and 30 norreal persons. In the meantime,30 normal persons were taken as control group. 30 EH cases were treated with Losartan,50 - 100mg/d. After treatment for 4 weeks the above data were detected again. Results The PAI-1, D-D, vWF in EH cases were obviously higher than those in control group （ P 〈 0. 01 ）. The PAI-1, D-D, vWF were decreased （ P 〈 0. 01 ） after treatment of Losartan. Conclusions The coagulation and fib rlndysis condition were changed in EH patients. The PAI-1 ,D-D,vWF were significantly higher in EH patients than those in control group. Losarta, not only decreased obviously systolic blood pressure and diastolic blood pressure but also improved the coagulation and fibrinolysis condition in EH patients.
出处
《中国厂矿医学》
2006年第3期199-202,共4页
Chinese Medicine of Factory and Mine
